Salvina Therapeutics AG, a recently founded Swiss company, is developing new therapies to break efficacy ceilings in inflammatory and autoimmune diseases.
The company has unlocked a novel epitope for selectively targeting TNF, resulting in the generation of antibodies with a highly innovative mode of action. These have the potential to significantly improve the benefit/risk ratio of TNF targeting in certain diseases and enable combination therapies that have not been developable to date. The anti-TNF market is worth over $ 40 billion per year and includes the best-selling drug of all time, Humira (adalimumab).
The founding team brings extensive academic, clinical and industry research experience together with a proven track record of building and exiting biotech companies. Dr. Mattias Ivarsson (CEO) and Dr. Helmut Sparrer (CSO) lead the team, with Dr. Tamas Schweighoffer as Chairman, and Prof. Mihai Netea and Prof. Leo Joosten as scientific advisors.
We are thrilled to welcome Salvina Therapeutics to our portfolio!
